Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Read More

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics Named the Stock Exchange Company of the Year

Read More

Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

Read More